UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): December 4, 2020

 

 

Xenetic Biosciences, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   001-37937   45-2952962

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

40 Speen Street, Suite 102
Framingham, Massachusetts		   01701
(Address of Principal Executive Offices)   (Zip Code)

 

(781) 778-7720

(Registrant’s Telephone Number, including Area Code)

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share XBIO The NASDAQ Stock Market LLC
     
Purchase Warrants XBIOW The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company           ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

   

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 4, 2020, Xenetic Biosciences, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals and corresponding votes.

 

1.The Company’s stockholders approved the election of the following eight nominees with each director receiving votes as follows:

 

Name   For   Withheld   Broker Non-Votes
Dr. Grigory Borisenko   2,065,947   97,389   2,081,732
Dr. James Callaway   2,070,426   92,910   2,081,732
Mr. Firdaus Jal Dastoor, FCS   2,069,578   93,758   2,081,732
Mr. Jeffrey Eisenberg   2,069,749   93,587   2,081,732
Dr. Dmitry Genkin   2,065,845   97,491   2,081,732
Dr. Roger Kornberg   2,066,570   96,766   2,081,732
Mr. Adam Logal   2,070,849   92,487   2,081,732
Dr. Alexey Vinogradov   2,064,735   98,601   2,081,732

 

2.The Company’s stockholders voted upon and approved the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020. The votes on this proposal were as follows:

 

For   Against   Abstained   Broker Non-Votes
4,153,308   12,628   79,132   –

 

  3. The Company’s stockholders voted upon and approved, on a non-binding, advisory basis, the Company’s named executive officer compensation. The votes on this proposal were as follows:

 

For   Against   Abstained   Broker Non-Votes
1,608,109   121,223   434,004   2,081,732

 

4.The Company’s stockholders voted upon and approved and adopted an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of the Company’s common stock from 12,500,000 shares to 50,000,000 shares. The votes on this proposal were as follows:

 

For   Against   Abstained   Broker Non-Votes
3,511,435   605,216   128,417   –

 

No other matters were considered or voted upon at the Annual Meeting.

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
    
  By:        /s/ James Parslow
Date: December 9, 2020  Name:   James Parslow
  Title:     Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3